(¿Â¶óÀÎ) Á¦14Â÷ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Çмú´ëȸ ¹× 2021 ±¹Á¦Çмú´ëȸ (2ÀÏÂ÷) : 2021-09-03±³À°ÀÏÀÚ : 2021-09-03
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À° (½Ç½Ã°£ È»ó±³À°)
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) Á¦14Â÷ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Çмú´ëȸ ¹× 2021 ±¹Á¦Çмú´ëȸ (2ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇÑÁ¾¾ç³»°úÇÐȸ(17.5 ¸íĪº¯°æ Çѱ¹ÀÓ»ó¾ÏÇÐȸ)
´ã´çÀÚ : °ÇØÁø
¿¬¶ôó : 02-735-2857
À̸ÞÀÏ :
ksmo3@ksmo.or.kr ±³À°Á¾·ù : ³»°ú, ¹æ»ç¼±Á¾¾çÇаú, º´¸®°úÀÇ·áÁ¤Ã¥
Âü¼®¿¹»óÀοø : 1000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 7 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 70,000¿ø
ºñ°í Àüµî·Ï : ȸ¿ø(±³¼ö,Àü¹®ÀÇ,ÀüÀÓÀÇ) -> 5¸¸¿ø ºñȸ¿ø -> 7¸¸¿ø/ ȸ¿ø(Àü°øÀÇ,°£È£»ç,¾à»ç,±ºÀÇ°ü) -> 3¸¸¿ø, ºñȸ¿ø ->5¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀÎ 09:00~09:40 Tumor heterogeneity and treatment resistance Joan S BRUGGE(Harvard Medical School)
ÈÞ½Ä 09-03 ½Ç½Ã°£¿Â¶óÀÎ 09:40~10:00 ()
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀÎ 10:00~10:22 Adjuvant treatment with IO : one size fits all?? : selection of patients who need adjuvant IO Rodabe N. Amaria(The University of Texas MD Anderson Cancer Center)
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀÎ 10:22~10:44 Conducting clinical trials of adjuvant treatment with targeted therapy ¹Ú¿¬Èñ(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀÎ 10:44~11:06 Incorporation of Palliative Care in ASCO Ishwaria Mohan Subbiah(The University of Texas MD Anderson Cancer Center)
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀÎ 11:06~11:28 Introduction of Korean Academy of Supportive Care in Cancer ±ÇÁ¤Çý(¼¼Á¾Ãæ³²´ëÇб³º´¿ø)
Åä·Ð 09-03 ½Ç½Ã°£¿Â¶óÀÎ 11:28~11:30 Q&A -(-)
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀÎ 11:30~12:10 Tecentriq + Avastin : Reigniting progress in the HCC treatment landscape À¯Ã¢ÈÆ(¼¿ï¾Æ»êº´¿ø)
ÈÞ½Ä 09-03 ½Ç½Ã°£¿Â¶óÀÎ 12:10~12:40 ()
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀÎ 12:40~13:05 Emergence of immunotherapy in HCC: what Ghassan ABOU-ALFA(MSKCC)
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀÎ 13:05~13:30 Dawn of a new era for biliary tract cancer: targeted and immunotherapy ¿Àµµ¿¬(¼¿ï´ëÇб³º´¿ø)
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀÎ 13:30~13:55 Beyond PARPi and novel therapy in pancreatic cancer Teresa MACARULLA(VHIO)
Åä·Ð 09-03 ½Ç½Ã°£¿Â¶óÀÎ 13:55~14:00 Q&A -(-)
ÈÞ½Ä 09-03 ½Ç½Ã°£¿Â¶óÀÎ 14:00~14:20 ()
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀÎ 14:20~14:42 Neoadjuvant chemotherapy followed by surgery in locally advanced pancreato-biliary cancer ÀåÁø¿µ(¼¿ï´ëÇб³º´¿ø)
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀÎ 14:42~15:04 Recent advances in neoadjuvant chemotherapy for locally advanced pancreato-biliary cancer À¯Ã¢ÈÆ(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀÎ 15:04~15:26 Primary breast surgery for newly diagnosed stage IV breast cancer patients Á¤¼Ò¿¬(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀÎ 15:26~15:48 How to manage stage IV breast cancer patients with oligometastasis ±èÇÑÁ¶(¼øõÇâ´ëõ¾Èº´¿ø)
Åä·Ð 09-03 ½Ç½Ã°£¿Â¶óÀÎ 15:48~15:50 Q&A Á¤¹Î±Ô(¿¬¼¼¾Ïº´¿ø)
ÈÞ½Ä 09-03 ½Ç½Ã°£¿Â¶óÀÎ 15:50~16:00 ()
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀÎ 16:00~16:20 Bacterial infections and human cancer Thomas F. MEYER(Max Planck Institute for Infection Biology)
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀÎ 16:20~16:40 HBV Infection–Based HCC TME and immunotherapy Valerie Chew Suk PENG(Translational Immunology Institute (TII))
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀÎ 16:40~17:00 Screening for early nasopharyngeal cancers by circulating Epstein-Barr virus DNA analysis KC Allen CHAN(The Chinese University of Hong Kong)
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀÎ 17:00~17:40 Drug development in oncology: the revolution of the last 15 years Jean-Charles SORIA(Amgen)